Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial
Article
[키워드] 1:1
95 % CI
Activation
addition
Administered
adverse event
approach
assigned
Basel
blockade
BMI
canakinumab
Clinical outcome
contributing to
COVID-19
CRP
Dexamethasone
diabetes
died
dose
double-blind
dropped
drug
Efficacy
foundation
glycaemic control
higher risk
hospitalised
Hospitalization
Hyperinflammatory
ICU
IL-1beta
IL-1β
IL-6
IMPROVE
Inflammasome
innate immune system
interleukin-1β
intravenous dose
less
medication
multicenter
multicentre
Novartis
Obesitiy.
obesity
outcome
participant
Patient
patients treated
patients with COVID-19
Placebo
placebo group
placebo-controlled trial
primary analysis
randomised
randomization
Randomly
reduction
Registered
reported
required
SARS-CoV2
SARS-CoV2 infection
Science
Seven
severe COVID-19
significantly
Standard-of-care
statistically significant
statistically significant difference
survival
Switzerland
systemic inflammation
tested
treated
Treatment
type 2 diabete
university
Ventilation
with COVID-19
[DOI] 10.1016/j.eclinm.2022.101649 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.eclinm.2022.101649 PMC 바로가기 [Article Type] Article